- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00528931
A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture
A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of a Single Injection of AA4500 0.58 mg in Subjects With Dupuytren's Contracture
A Phase 1, open-label, single-dose pharmacokinetic study in subjects with Dupuytren's contracture conducted at one site in the United States. All subjects received a single dose of AA4500 0.58 mg, which was injected directly into the cord affecting either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint. Pharmacokinetic blood samples were collected before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30. Efficacy and safety assessments were performed up to 30 days after the AA4500 0.58 injection.
This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 [NCT00528606]and AUX-CC-859 [NCT00533273]) and 7 non-pivotal studies were evaluated.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
Burbank, California, Forente stater, 91505
- Providence Clinical Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
- Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
- Were naive to AA4500 treatment.
- Were judged to be in good health.
Exclusion Criteria:
- Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
- Had received treatment for Dupuytren's contracture within 90 days of the AA4500 injection to the MP or PIP selected, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.
- Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: AA4500 0,58 mg
|
Single dose of AA4500 0.58 mg into the cord
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500
Tidsramme: Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30
|
AUX I and AUX II are the constituent protein collagenases of collagenase clostridium histolyticum (AA4500).
Plasma concentrations of AUX I and AUX II were assessed through an enzymye-linked-immunoabsorbent assay (ELISA).
|
Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Clinical Success
Tidsramme: 30 days after treatment to the primary joint
|
Clinical success defined as a reduction in contracture (ie, flexion deformity) to ≤5° of normal as measured by finger goniometry 30 days after an injection.
Last observation carried forward (LOCF) after the injection was used if the status at day 30 could not be determined.
|
30 days after treatment to the primary joint
|
Clinical Improvement
Tidsramme: 30 days after treatment to the primary joint
|
Clinical improvement defined as ≥50% reduction from baseline in contracture within 30 days of the injection.
LOCF after the injection was used if the status at day 30 could not be determined.
|
30 days after treatment to the primary joint
|
Percent Change From Baseline Contracture
Tidsramme: Baseline, 30 days after treatment to the primary joint
|
Change from baseline in the degree of fixed-flexion contracture calculated as 100 times (baseline contracture minus last available post-injection contracture measurement) divided by baseline contracture where a positive change indicates a reduction in the degree of contracture.
|
Baseline, 30 days after treatment to the primary joint
|
Change From Baseline Range of Motion
Tidsramme: Baseline, 30 days after treatment to the primary joint
|
Range of motion defined as the difference between the finger extension angle and finger flexion angle expressed in degrees
|
Baseline, 30 days after treatment to the primary joint
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Veronica Urdaneta, MD, Endo Pharmaceuticals
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AUX-CC-855
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på collagenase clostridium histolyticum
-
Endo PharmaceuticalsFullført
-
Endo PharmaceuticalsFullførtØdematøs hudForente stater
-
Zachary GerutAdvance Biofactures CorporationFullført
-
University of MiamiEndo PharmaceuticalsRekrutteringSeksuelle dysfunksjoner, psykologiske | Kjønnssykdommer, mannlige | Peyronie sykdomForente stater
-
Endo PharmaceuticalsFullførtSelvklebende kapsulitt | Frossen skulderForente stater
-
Endo PharmaceuticalsFullførtSlapphet; Hud | Cellulitt | Ødematøs fibrosklerotisk pannikulopatiForente stater
-
Advance Biofactures CorporationFullførtLeiomyoma | Fibromer, livmorForente stater
-
Endo PharmaceuticalsFullførtCellulitt | Ødematøs fibrosklerotisk pannikulopatiForente stater
-
Endo PharmaceuticalsFullførtCellulitt | Ødematøs fibrosklerotisk pannikulopatiForente stater
-
Endo PharmaceuticalsFullførtØdematøs fibrosklerotisk pannikulopatiForente stater